Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

NCT04865887 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT04865887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04865887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Recruiting
Start date
October 7, 2022
Completion date
July 31, 2028
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, metastatic cervical cancer